EP1202983A1 - Verfahren zur herstellung von lösemittelfreier alpha-liponsäure - Google Patents
Verfahren zur herstellung von lösemittelfreier alpha-liponsäureInfo
- Publication number
- EP1202983A1 EP1202983A1 EP00954620A EP00954620A EP1202983A1 EP 1202983 A1 EP1202983 A1 EP 1202983A1 EP 00954620 A EP00954620 A EP 00954620A EP 00954620 A EP00954620 A EP 00954620A EP 1202983 A1 EP1202983 A1 EP 1202983A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- acid
- lipoic acid
- stage
- lipoic
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
Definitions
- the present invention relates to a method for producing solvent-free ⁇ -lipoic acid.
- ⁇ -Lipoic acid (thioctic acid, 1, 2-dithiolan-3-pentanoic acid) is a natural substance that occurs in low concentrations in plant and animal cells in the form of the R enantiomer.
- the ⁇ -lipoic acid originally discovered as a growth factor acts physiologically in hydrophilic and lipophilic media as a coenzyme for the oxidative decarboxylation of ⁇ -ketocarboxylic acids (e.g. pyruvates) and as an antioxidant and is capable of regenerating vitamin C, vitamin E, glutathione and coenzyme Q1 0.
- Racemic ⁇ -lipoic acid is approved for the treatment of liver diseases and neuropathies (e.g.
- ⁇ -lipoic acid also has cytoprotective, anti-inflammatory and antinociceptive (analgesic) properties, whereby it turned out that in contrast to the pure optical isomers of ⁇ -lipoic acid (R- ⁇ -lipoic acid or S- ⁇ -lipoic acid) for the racemate, the R enantiomer shows a predominantly antiphlogistic and the S enantiomer shows a predominantly antinociceptive activity profile (cf. EP 0 81 2 590 A2).
- the usual cleaning method for crude ⁇ -lipoic acid is recrystallization from solvents (e.g. from n-pentane, cyclohexane, methylcyclohexane, ethyl acetate) or mixtures of solvents (e.g. from ethyl acetate and hexane), as described for example in Brookes et al. , J. Chem. Soc. Perkin Trans. 1 1 988, 9, Segre et al., J. Am. Chem. Soc. 1 957, 3503, Walton et al., J. Am. Chem. Soc. 1 955, 77, 5144, Acker et al., J. Am. Chem. Soc.
- the present invention is therefore based on the object of creating a process for the production of solvent-free ⁇ -lipoic acid which does not have the disadvantages of the known processes but instead enables the production of ⁇ -lipoic acid which no longer contains any organic residual solvents. This object was achieved in that
- the ⁇ -lipoic acid to be cleaned dissolves in aqueous, alkaline solution or its salt dissolves in water and sets an alkaline pH value
- the ⁇ -lipoic acid to be purified is expediently dissolved in step a) in aqueous alkaline solution with a pH of 7.5 to 1 6.0, preferably 9.0 to 1 4.0.
- the alkaline solution can contain the usual bases in the form of hydroxides, carbonates and hydrogen carbonates of alkali or alkaline earth metals (such as sodium, potassium, calcium and magnesium), ammonia or primary, secondary or tertiary amines (such as benzylamine, diisopropylamine, triethylamine) ,
- the crude ⁇ -lipoic acid used in stage a) can be produced by any method.
- the ⁇ -lipoic acid can, for example be produced by recrystallization with an organic solvent or be crude ⁇ -lipoic acid in the absence of organic solvents.
- racemic ⁇ -lipoic acid and an enantiomerically pure R- (+) - ⁇ -lipoic acid or S - (-) - ⁇ -lipoic acid or any mixtures thereof can be used in the process according to the invention.
- a salt of the ⁇ -lipoic acid can also be dissolved in water and then made alkaline, e.g. with the bases already described, expediently to a pH of 7.5 to 1 6.0, preferably 9.0 to 1 4.0.
- alkali metal such as sodium or potassium
- alkaline earth metal salts such as calcium or magnesium
- other salts of ⁇ -lipoic acid can also be used, the cations of which can consist in particular of the elements zinc, iron, copper, palladium, vanadium and selenium.
- ⁇ -lipoic acid salts of organic cations such as open-chain or cyclic ammonium compounds (such as ammonium, methylammonium, benzylmethylammonium or tetramethylammonium cations), complex cations (with metallic central atoms such as iron (III), chromium (III) or cobalt (II) and neutral, cationic or anionic ligands (such as water (H 2 O), ammonia (NH 3 ), carbonyl (CO), cyano (CN) or nitroso (NO)) or oxocations (such as For example, oxovanadium (V) (VO 2 + ) or oxovanadium (IV) (V0 2 + )) can be used as starting compounds.
- open-chain or cyclic ammonium compounds such as ammonium, methylammonium, benzylmethylammonium or tetramethylammonium cations
- complex cations with metallic central
- the ⁇ -lipoic acid content in stage a) can be varied within wide limits. However, it has proven to be advantageous to adjust the concentration of ⁇ -lipoic acid in the aqueous alkaline solution to 0.01 to 15% by weight, preferably to 0.1 to 5% by weight.
- activated carbon is added to the aqueous alkaline solution in stage a) before performing stage b) in an amount of from 0.01 to 50% by weight, based on the ⁇ -lipoic acid equivalents in the solution. With the help of these activated carbons, it is also possible to separate disruptive impurities, by-products and / or residual solvents. Activated carbons of the brand Norit SX Plus, Norit Pureflow 1, Norit Pureflow C or Norit SA Plus have proven to be particularly advantageous.
- any solid impurities present are removed from the aqueous solution in stage a).
- the usual methods such as filtration, centrifugation and the like are suitable.
- the aqueous solution from stage a) or b) is adjusted in the subsequent stage c) with the aid of an acid to a pH of from 1.0 to 5.0, preferably from 1.0 to 4.0.
- an acid to a pH of from 1.0 to 5.0, preferably from 1.0 to 4.0.
- Both inorganic and organic acids can be used to adjust the pH.
- the usual mineral acids e.g. Hydrohalic acid (in the form of hydrochloric acid or hydrobromic acid), nitric acid, sulfuric acid and phosphoric acid have proven particularly effective.
- the pH adjustment can also be carried out with organic acids, e.g. an aliphatic carboxylic acid with 1 to 6 carbon atoms (e.g. formic acid, acetic acid), an aromatic carboxylic acid (e.g.
- benzoic acid a halogenated or oxygenated carboxylic acid (e.g. chloroacetic acid, trifluoroacetic acid, pyruvic acid) or an aliphatic or aromatic sulfonic acid (e.g. methanesulfonic acid, toluenesulfonic acid).
- carboxylic acid e.g. chloroacetic acid, trifluoroacetic acid, pyruvic acid
- an aliphatic or aromatic sulfonic acid e.g. methanesulfonic acid, toluenesulfonic acid
- the temperature in stages a) to c) is not critical, but is expediently chosen in the range from -50 to + 60 ° C., room temperatures being preferred.
- the lipoic acid precipitated by the pH adjustment is separated off, preferably by filtration or centrifugation.
- the temperature in stage d) is expediently chosen in the range from -50 to + 60 ° C., preferably in the range from -1 0 to + 10 ° C.
- the purified ⁇ -lipoic acid obtained from stage d) contains the physiologically completely harmless solvent water as the only secondary component.
- the storage stability of moist, semi-moist or dry ⁇ -lipoic acid is not affected by the water content.
- the water content of the cleaned and dried ⁇ -lipoic acid can be reduced to values of ⁇ 0.5, in particular ⁇ 0.1% by weight, by conventional drying, for example in a fluidized bed dryer, paddle dryer, cone screw mixer dryer or double-cone mixer dryer ,
- Organic solvents can no longer be detected in the ⁇ -lipoic acid produced by the process according to the invention. Detection and limits of determination for a number of common organic solvents that can be used in the production and / or purification of ⁇ -lipoic acid are summarized in Table 1 below as examples.
- the method according to the invention thus represents a significant improvement in the field of purification of racemic or enantiomerically pure ⁇ -lipoic acid, because the quality requirements for active pharmaceutical ingredients and medical products are fully taken into account by completely removing all traces of residual solvent.
- the ⁇ -lipoic acid obtained (approx. 1 g) is dissolved in 10 ml of p-chlorotoluene and an aliquot of this solution is injected directly into a gas chromatograph.
- the detection is done by FID (flame ionization detection) against an external standard. Detection and determination limits are summarized in Table 1.
- Figure 1 shows a gas chromatogram of a crude ⁇ -lipoic acid (Example 1)
- Figure 2 shows the gas chromatogram of the associated purified ⁇ -lipoic acid. Only the section that contains the residual solvents is shown ( ⁇ -lipoic acid itself elutes under the GC conditions at approx. 20 min).
- the paddle dryer had a residual solvent content of 1.2% by weight and was introduced into 1000 l of water at 20.degree. With 50% water
- % aqueous hydrochloric acid brought to a pH of 2.0.
- the precipitated ⁇ -lipoic acid was separated from the mother liquor in a centrifuge and washed with water until the wash water had a neutral pH. After drying in a paddle dryer (35 ° C, 5 mbar, 1 5 h) the standard parameters of an analysis of the
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19938621A DE19938621A1 (de) | 1999-08-14 | 1999-08-14 | Verfahren zur Herstellung von lösemittelfreier alpha-Liponsäure |
DE19938621 | 1999-08-14 | ||
PCT/EP2000/007802 WO2001012620A1 (de) | 1999-08-14 | 2000-08-10 | VERFAHREN ZUR HERSTELLUNG VON LÖSEMITTELFREIER α-LIPONSÄURE |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1202983A1 true EP1202983A1 (de) | 2002-05-08 |
EP1202983B1 EP1202983B1 (de) | 2003-01-29 |
Family
ID=7918432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00954620A Expired - Lifetime EP1202983B1 (de) | 1999-08-14 | 2000-08-10 | Verfahren zur herstellung von lösemittelfreier alpha-liponsäure |
Country Status (11)
Country | Link |
---|---|
US (1) | US6462202B1 (de) |
EP (1) | EP1202983B1 (de) |
CN (1) | CN1131227C (de) |
AT (1) | ATE231854T1 (de) |
AU (1) | AU6701300A (de) |
CA (1) | CA2380495C (de) |
DE (2) | DE19938621A1 (de) |
DK (1) | DK1202983T3 (de) |
ES (1) | ES2187483T3 (de) |
PT (1) | PT1202983E (de) |
WO (1) | WO2001012620A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1319195B1 (it) * | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | Processo per la produzione dell'acido r(+)alfa-lipoico. |
IT1319196B1 (it) * | 2000-10-10 | 2003-09-26 | Laboratorio Chimico Int Spa | Sintesi dell'acido r(+)alfa-lipoico. |
DE10159245A1 (de) * | 2001-12-03 | 2003-06-18 | Degussa | Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung |
DE10201464B4 (de) * | 2002-01-16 | 2005-06-16 | Viatris Gmbh & Co. Kg | Verfahren zur Herstellung reiner Thioctsäure |
ITMI20050466A1 (it) * | 2005-03-22 | 2006-09-23 | Laboratorio Chimico Int Spa | Processo di purificazione in acqua di acido tiottico |
CN100375745C (zh) * | 2005-12-21 | 2008-03-19 | 重庆药友制药有限责任公司 | 硫辛酸的精制方法 |
CN100387593C (zh) * | 2006-01-26 | 2008-05-14 | 南京师范大学 | 连续逆流液液萃取分离二硫辛酸与乙醇及碱水溶液的方法 |
DE102007038849A1 (de) | 2007-08-16 | 2009-02-19 | Adscil Gmbh | Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie |
KR20110103987A (ko) * | 2008-12-01 | 2011-09-21 | 인베이스크 테라퓨틱, 인크. | 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도 |
CN102603709B (zh) * | 2012-03-02 | 2013-09-25 | 海南灵康制药有限公司 | 一种硫辛酸化合物及其制法 |
CN105798322B (zh) * | 2016-03-17 | 2018-04-24 | 湖北大学 | 银纳米簇的制备方法及其应用 |
CN114163418A (zh) * | 2021-12-24 | 2022-03-11 | 山东龙辰药业有限公司 | 一种右旋硫辛酸的合成方法 |
CN115490861B (zh) * | 2022-08-22 | 2023-11-17 | 北京化工大学 | 一种聚硫辛酸可再生高分子材料制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19726519A1 (de) * | 1997-06-23 | 1998-12-24 | Asta Medica Ag | Verfahren zur Herstellung trockener Thioctsäure |
-
1999
- 1999-08-14 DE DE19938621A patent/DE19938621A1/de not_active Withdrawn
-
2000
- 2000-08-10 WO PCT/EP2000/007802 patent/WO2001012620A1/de active IP Right Grant
- 2000-08-10 EP EP00954620A patent/EP1202983B1/de not_active Expired - Lifetime
- 2000-08-10 DE DE50001184T patent/DE50001184D1/de not_active Expired - Lifetime
- 2000-08-10 DK DK00954620T patent/DK1202983T3/da active
- 2000-08-10 US US10/030,491 patent/US6462202B1/en not_active Expired - Lifetime
- 2000-08-10 PT PT00954620T patent/PT1202983E/pt unknown
- 2000-08-10 AT AT00954620T patent/ATE231854T1/de active
- 2000-08-10 CA CA002380495A patent/CA2380495C/en not_active Expired - Fee Related
- 2000-08-10 CN CN00808557A patent/CN1131227C/zh not_active Expired - Fee Related
- 2000-08-10 AU AU67013/00A patent/AU6701300A/en not_active Abandoned
- 2000-08-10 ES ES00954620T patent/ES2187483T3/es not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
See references of WO0112620A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1131227C (zh) | 2003-12-17 |
ES2187483T3 (es) | 2003-06-16 |
WO2001012620A1 (de) | 2001-02-22 |
ATE231854T1 (de) | 2003-02-15 |
CN1354748A (zh) | 2002-06-19 |
DE50001184D1 (de) | 2003-03-06 |
DK1202983T3 (da) | 2003-05-26 |
US6462202B1 (en) | 2002-10-08 |
AU6701300A (en) | 2001-03-13 |
CA2380495C (en) | 2006-10-17 |
CA2380495A1 (en) | 2001-02-22 |
EP1202983B1 (de) | 2003-01-29 |
PT1202983E (pt) | 2003-06-30 |
DE19938621A1 (de) | 2001-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1202983B1 (de) | Verfahren zur herstellung von lösemittelfreier alpha-liponsäure | |
DE3940091C2 (de) | ||
DE102005022276A1 (de) | Derivate von Dihydroxyphenylalanin | |
DE4427079C2 (de) | Verfahren zur Racemisierung von Enantiomeren der alpha-Liponsäure | |
EP0543088A1 (de) | Herstellung und Verwendung von Salzen der reinen Enantiomere der alpha-Liponsäure | |
DE1171931B (de) | Verfahren zur Herstellung antihypertonisch wirkender Phenylalaninderivate | |
DE2846251C2 (de) | ||
DE19707694A1 (de) | Kreatin-ascorbate und Verfahren zu deren Herstellung | |
EP0520414B1 (de) | Verfahren zur Gewinnung von Diacetylrhein | |
DE3306092A1 (de) | Neue kristallmodifikationen, verfahren zu deren herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen | |
DE2439859A1 (de) | Verfahren zur herstellung von 3-(3,4dihydroxy-phenyl)-serin | |
CH626343A5 (de) | ||
DE10159245A1 (de) | Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung | |
DE2625012C3 (de) | Arzneimittel zur Kontrolle von Leberkrankheiten | |
DE19810336A1 (de) | Alpha-Liponsäure mit neuartiger Modifikation | |
AT392068B (de) | Optisch aktive oxo-isoindolinylderivate | |
DE2243777A1 (de) | Dihydrochinolinderivate, ihre verwendung und verfahren zur herstellung derselben | |
WO2001024795A1 (de) | α-LIPONSÄURE(-DERIVATE)ENTHALTENDE RETARDFORM | |
DE2440381A1 (de) | Substituierte phenoxyalkancarbonsaeuren, salze hiervon sowie verfahren zu ihrer herstellung | |
DE10045904B4 (de) | alpha-Liponsäure(-Derivate) enthaltende Retardform | |
WO2003099256A2 (de) | FLIESSFÄHIGE, PULVERFÖRMIGE α-LIPONSÄURE(-DERIVATE) ENTHALTENDE ZUSAMMENSETZUNG | |
DE479228C (de) | Verfahren zur Herstellung von ª‰-Aryl-ª‰-aminofettsaeuren und deren in der Seitenkette am Stickstoffatom mono- und dialkylierten Derivaten | |
EP1567516A1 (de) | Verfahren zur reinigung von lipons ure | |
DE1620170C3 (de) | Neue Phenothiazinderivate und Verfahren zu ihrer Herstellung | |
DE2318325C3 (de) | 5-Hydroxytryptophan-alpha-ketoglutarat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011018 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DEGUSSA AG |
|
17Q | First examination report despatched |
Effective date: 20020612 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
REF | Corresponds to: |
Ref document number: 50001184 Country of ref document: DE Date of ref document: 20030306 Kind code of ref document: P |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20030304 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030401026 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2187483 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20030429 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20030129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030810 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030810 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030901 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20031030 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041015 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050303 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
BECA | Be: change of holder's address |
Owner name: ALZCHEM TROSTBERG G.M.B.H.DR.-ALBERT-FRANK-STRASSE Effective date: 20080116 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: DEGUSSA GMBH Free format text: DEGUSSA AG#STANDORT TROSTBERG, DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) -TRANSFER TO- DEGUSSA GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) Ref country code: CH Ref legal event code: PFA Owner name: EVONIK DEGUSSA GMBH Free format text: DEGUSSA GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) -TRANSFER TO- EVONIK DEGUSSA GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) Ref country code: CH Ref legal event code: PUE Owner name: ALZCHEM TROSTBERG GMBH Free format text: EVONIK DEGUSSA GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) -TRANSFER TO- ALZCHEM TROSTBERG GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) |
|
NLS | Nl: assignments of ep-patents |
Owner name: ALZCHEM TROSTBERG GMBH Effective date: 20080103 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030129 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: ALZCHEM TROSTBERG GMBH Free format text: ALZCHEM TROSTBERG GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) -TRANSFER TO- ALZCHEM TROSTBERG GMBH#DR.-ALBERT-FRANK-STRASSE 32#83308 TROSTBERG (DE) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030810 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20100824 Year of fee payment: 11 Ref country code: IE Payment date: 20100820 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20100812 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110831 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110811 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20140820 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20140611 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20150819 Year of fee payment: 16 Ref country code: ES Payment date: 20150827 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20150819 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 231854 Country of ref document: AT Kind code of ref document: T Effective date: 20150810 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20150901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150901 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160831 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20160810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160810 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160811 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20180725 Year of fee payment: 9 Ref country code: IT Payment date: 20180830 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20181123 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20190822 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 50001184 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190810 |